期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

17例Ph染色体阳性急性淋巴细胞白血病患者单倍体异基因造血干细胞移植疗效分析 被引量：6

Outcomes of haplotype allogeneic hematopoietic stem cell transplantation in 17 patients with Philadelphiachromosome-positive acute lymphoblastic leukemia
原文传递
导出
摘要 研究表明，20％～30％成人急性淋巴细胞白血病（ALL）患者表达BCR-ABL癌基因产物，这种癌基因产物是由费城染色体（Ph）的t（9；22）染色体易位所致，Ph染色体阳性（Ph＋）已经成为ALL重要的独立预后因素…。
作者 周洁 周海侠 张日 吴德沛
机构地区 苏州大学附属第一医院血液科、江苏省血液研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第2期170-172,共3页 Chinese Journal of Hematology
关键词 急性淋巴细胞白血病 PH染色体阳性 异基因造血干细胞移植 白血病患者 疗效分析 单倍体 BCR-ABL 癌基因产物
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Hematol Oncol Clin North Am, 2009,23(5): 1043-1063.
  • 2Kanda Y, Chiba S, Hirai H, et a1. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identi?cal siblings over the last decade (1991-2000)[J]. Blood, 2003, 102(4): 1541-1547.
  • 3Wassmann B, Pfeifer H, Goekbuget N, et a1. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)[J]. Blood, 2006,108(5): 1469-1477.
  • 4Thomas DA, Fader! S, CortesJ, et a1. Treatment of Philadelphia chromosome- positive acute lymphocytic leukemia with hyper?CVAD and imatinib mesylate[J]. Blood, 2004, 103 (12): 4396- 4407.
  • 5Yanada M, TakeuchiJ, Sugiura I, et a1. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR- ABL- positive acute lymphoblastic leukemia: a phase II study by theJapan Adult Leukemia Study Group[J].J Clin Oncol, 2006, 24(3): 460-466.
  • 6Fielding AK, RoweJM, Richards SM, et a1. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre- imatinib era: results from the International ALL Trial MRC UKALLXUIEC0G2993[J]. Blood, 2009,113(19): 4489- 4496.
  • 7Schultz KR, Bowman WP, Aledo A, et a1. Improved ear!y event?free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study[J].J Clin Oncol, 2009, 27(31): 5175-5181.
  • 8Wang Y, Liu DH, Xu LP, et a1. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison[J]. Bioi Blood Marrow Transplant, 2011,17(6): 821-830.
  • 9Villalobos lB, Takahashi Y, Akatsuka Y, et a1. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation[J]. Blood, 2010,115(15): 3158-3161.
  • 10Cooley S, Weisdorf OJ, Guethlein LA, et a1. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia[J]. Blood, 2010,116(14): 2411-2419.

二级参考文献25

  • 1Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seat- tie experience. Bone Marrow Transplant, 2000, 26:397-404.
  • 2Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in pa- tients with acute leukemia at high risk of relapse. J Clin Oncol, 2005, 23:3447-3454.
  • 3Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukaemia with unmanipnlated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant, 2009, 15:257-265.
  • 4Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for ad- vanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant, 2000, 26 : 1157-1163.
  • 5Doney K, H~igglund H, Leisenring W, et al. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute ymphoblastic eukemia. Biol Blood Marrow Transplant, 2003, 9:472-481.
  • 6Singhal S, Powles R, Henslee-Downey PJ, et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mis- matched related donors for primary refractory acute leukemia. Bone Marrow Transplant, 2002, 29:291-295.
  • 7Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation fi'om family members other than HLA-identical siblings over the last decade ( 1991-2000 ). Blood, 2003, 102 : 1541-1547.
  • 8Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol, 1997, 15:1767-1777.
  • 9Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone MmTow Trans- plant, 2006, 38: 291-297.
  • 10Huang X J, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant, 2009, 15:257-265.

共引文献25

同被引文献80

  • 1Pidala J, Djulbegovic B, Anasetti C, et al. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission[J]. Cochrane Database Syst Rev, 2011, (10): CD008818.
  • 2Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center[J]. Cancer, 2013, 119(5):978-985.
  • 3Wu X, He G, Fa Y, et al. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Int J Hematol, 2013,98(4):456-462.
  • 4Sun YQ, Wang J, Jiang Q, et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL[J]. Bone Marrow Transplant, 2015,50(1):20-25.
  • 5Yan CH, Jiang Q, Wang J, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission[J]. Biol Blood Marrow Transplant, 2014, 20(9):1314-1321.
  • 6Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993[J]. Blood, 2005, 106(12): 3760-3767.
  • 7Nishiwaki S, Miyamura K, Ohashi K, et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation[J]. Ann Oncol, 2013, 24(6): 1594-1602.
  • 8Mo XD, Xu LP, Zhang XH, et al. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: No difference in the high- and low-risk groups[J]. Int J Cancer, 2015,136(7):1697-1707.
  • 9Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome[J]. Hematol Cell Ther,1998,40(3):119-128.
  • 10Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial[J]. J Clin Oncol, 2004, 22(20): 4075-4086.

引证文献6

二级引证文献29

中华血液学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部